LYRA

Lyra Therapeutics, Inc. (NASDAQ:LYRA) is a clinical-stage biotechnology company founded in 2005 and headquartered in Watertown, Massachusetts. Originally incorporated as 480 Biomedical, Inc., the company rebranded to Lyra Therapeutics in July 2018 and went public in May 2020. Lyra specializes in developing innovative drug delivery solutions for ear, nose, and throat (ENT) conditions, with a focus on creating localized treatments that can be administered directly to affected tissues for sustained therapeutic effects.